Although it will be negatively impacted in the short term by the COVID-19 pandemic, the biosurgical agent market in Latin America will grow at a modest rate through 2029, primarily driven by favorable demographics, rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the US across a 10-year period.

The COVID-19 pandemic will affect the Latin America biosurgical agent market.

Which procedure types will be most strongly impacted by challenges associated with COVID-19

How will the impact of the pandemic vary by country?

At what pace is the biosurgical agent market expected to recover?

The Latin American market is underpenetrated, and the competitive landscape is highly dynamic.

Which products will see more rapid adoption, and why?

What recent changes have occurred in the competitive landscape of this market?

Economic constraints across Latin America have influenced purchasing decisions among health care facilities.

Which product segments will be the most influenced by budgetary restrictions?

How do these challenges affect manufacturer pricing decisions in Latin American countries?

Surgical procedure volume growth drives use of biosurgical agents in the Latin America region.

Which surgical specialties contribute most to biosurgical agent revenues in the Latin America region?

How will declining procedure volumes in certain surgical specialties affect market growth?

What impact will the expanding use of minimally invasive surgical techniques have on the biosurgical agent market?

Table of contents

  • Biosurgical Agents - Market Insights - Latin America

Author(s): Sumit Jain, MS Pharm

Sumit Jain is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.